logologo
QuantliQuantli

Johnson & Johnson

JNJ

NYSE

Pharmaceuticals

$267.37

USD

-6.04 (-2.21%)

At close: Aug 20, 2026, 4:00 PM EDT

Market Cap $629.71B

Volume 6.5M

Price (USD)
Price (USD)

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 138,200 full-time employees. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).

CEO

Mr. Joaquin Duato

HQ

New Brunswick, NEW JERSEY, US

Founded

1944

Employees

138,200

Quantli Score

8.4

Outperform

Fin. Health

8.1

Profitability

7.6

Growth

9.0

Cash-Flow Q.

8.8

Key Metrics

7 metrics our research team weighs before forming a view on JNJ.

Based on Quantli research · SEC filings · as of Q2 2026

METRIC

VALUE

CHANGE

TREND (3Y)

Revenue Growth (TTM)

8.1%

+3.4 pp

Gross Margin (TTM)

67.9%

-0.0 pp

Operating Margin (TTM)

26.5%

+2.8 pp

Net Margin (TTM)

21.5%

-3.5 pp

ROE (TTM)

24.8%

-4.1 pp

EPS Growth (TTM)

-7.8%

+30.9 pp

Free Cash Flow (TTM)

$22.23B

+32.6%

Financial Snapshot

Full Financials

Revenue

$97.93B

+8.1%

YoY

Gross Margin

68%

TTM

-0.0%

YoY

Net Income

$21.04B

-7.2%

YoY

Operating Cash Flow

$27.61B

+19.9%

YoY

Key Statistics

Open

$273.40

Previous Close

$273.41

Day Range

$267.37 - $273.40

52 Week Range

$173.33 - $276.47

Volume

6.5M

Average Volume (10 Days)

6.4M

Dividend Yield

2.00%

Valuation Measurement

Market Cap

$629.71B

P/E Ratio (TTM)

29.93

P/S Ratio (TTM)

6.43

Price / Book

7.41

Financial Highlights

Profit Margin

21.5%

Return on Assets

10.5%

Return on Equity

24.8%

Revenue (TTM)

$97.93B

Net Income (TTM)

$21.04B

Diluted EPS (TTM)

$8.62

Total Cash (MRQ)

$20.42B

Levered FCF (TTM)

$22.23B

Turn research into action

Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.

Trend Following

Enter on trend. Cut losses fast.

Best for:

Active traders

Position Strategy

Ride market cycles. Patient hold.

Best for:

Patient investors

Swing Strategy

Buy support, sell on recovery.

Best for:

Risk-tolerant

Go deeper on JNJ

Similar Stocks

BMY

Bristol-Myers Squibb Co

$65.47

-3.2%

ZTS

Zoetis Inc

$75.02

-2.2%

ELAN

Elanco Animal Health Inc

$23.56

-3.8%

PFE

Pfizer Inc

$27.79

-1.6%

MRK

Merck & Co Inc

$148.99

-2.1%

LLY

Eli Lilly and Co

$1244.40

-2.8%

Earnings Calendar

Next Earnings

Estimated Q3 Release

Oct 13

Est. EPS

Adjusted consensus estimate

$2.95

Analyst Consensus

Buy

Based on 1 analyst ratings

Avg Target: $270.00

(+1.0% upside)

High: $270.00 · Low: $270.00

Strong Buy

0%

Buy

100%

Hold

0%

Sell

0%

Strong Sell

0%

View full analyst ratings